These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 34751270)

  • 21. Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants.
    Zakir TS; Meng T; Carmen LCP; Chu JJH; Lin RTP; Prabakaran M
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potent neutralization of SARS-CoV-2 including variants of concern by vaccines presenting the receptor-binding domain multivalently from nanoscaffolds.
    Halfmann PJ; Castro A; Loeffler K; Frey SJ; Chiba S; Kawaoka Y; Kane RS
    Bioeng Transl Med; 2021 Sep; 6(3):e10253. PubMed ID: 34589610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice.
    Noy-Porat T; Mechaly A; Levy Y; Makdasi E; Alcalay R; Gur D; Aftalion M; Falach R; Leviatan Ben-Arye S; Lazar S; Zauberman A; Epstein E; Chitlaru T; Weiss S; Achdout H; Edgeworth JD; Kikkeri R; Yu H; Chen X; Yitzhaki S; Shapira SC; Padler-Karavani V; Mazor O; Rosenfeld R
    iScience; 2021 May; 24(5):102479. PubMed ID: 33937725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants.
    Yang Z; Wang Y; Jin Y; Zhu Y; Wu Y; Li C; Kong Y; Song W; Tian X; Zhan W; Huang A; Zhou S; Xia S; Tian X; Peng C; Chen C; Shi Y; Hu G; Du S; Wang Y; Xie Y; Jiang S; Lu L; Sun L; Song Y; Ying T
    Signal Transduct Target Ther; 2021 Nov; 6(1):378. PubMed ID: 34732694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential.
    Gai J; Ma L; Li G; Zhu M; Qiao P; Li X; Zhang H; Zhang Y; Chen Y; Ji W; Zhang H; Cao H; Li X; Gong R; Wan Y
    MedComm (2020); 2021 Mar; 2(1):101-113. PubMed ID: 33821254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies.
    Jette CA; Cohen AA; Gnanapragasam PNP; Muecksch F; Lee YE; Huey-Tubman KE; Schmidt F; Hatziioannou T; Bieniasz PD; Nussenzweig MC; West AP; Keeffe JR; Bjorkman PJ; Barnes CO
    Cell Rep; 2021 Sep; 36(13):109760. PubMed ID: 34534459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape.
    Wang L; Shi W; Chappell JD; Joyce MG; Zhang Y; Kanekiyo M; Becker MM; van Doremalen N; Fischer R; Wang N; Corbett KS; Choe M; Mason RD; Van Galen JG; Zhou T; Saunders KO; Tatti KM; Haynes LM; Kwong PD; Modjarrad K; Kong WP; McLellan JS; Denison MR; Munster VJ; Mascola JR; Graham BS
    J Virol; 2018 May; 92(10):. PubMed ID: 29514901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-SARS-CoV-2 Omicron Antibodies Isolated from a SARS-CoV-2 Delta Semi-Immune Phage Display Library.
    Mendoza-Salazar I; Gómez-Castellano KM; González-González E; Gamboa-Suasnavart R; Rodríguez-Luna SD; Santiago-Casas G; Cortés-Paniagua MI; Pérez-Tapia SM; Almagro JC
    Antibodies (Basel); 2022 Feb; 11(1):. PubMed ID: 35225871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of Receptor Binding Domain (RBD)-Conjugated Nanoparticle Vaccines with Broad Neutralization against SARS-CoV-2 Delta and Other Variants.
    Chen R; Zhang X; Yuan Y; Deng X; Wu B; Xi Z; Wang G; Lin Y; Li R; Wang X; Zou F; Liang L; Yan H; Liang C; Li Y; Wu S; Deng J; Zhou M; Zhang X; Li C; Bu X; Peng Y; Ke C; Deng K; He X; Zhang Y; Zhang Z; Pan T; Zhang H
    Adv Sci (Weinh); 2022 Apr; 9(11):e2105378. PubMed ID: 35142444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipid Nanoparticle RBD-hFc mRNA Vaccine Protects hACE2 Transgenic Mice against a Lethal SARS-CoV-2 Infection.
    Elia U; Rotem S; Bar-Haim E; Ramishetti S; Naidu GS; Gur D; Aftalion M; Israeli M; Bercovich-Kinori A; Alcalay R; Makdasi E; Chitlaru T; Rosenfeld R; Israely T; Melamed S; Abutbul Ionita I; Danino D; Peer D; Cohen O
    Nano Lett; 2021 Jun; 21(11):4774-4779. PubMed ID: 34032435
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2.
    Custódio TF; Das H; Sheward DJ; Hanke L; Pazicky S; Pieprzyk J; Sorgenfrei M; Schroer MA; Gruzinov AY; Jeffries CM; Graewert MA; Svergun DI; Dobrev N; Remans K; Seeger MA; McInerney GM; Murrell B; Hällberg BM; Löw C
    Nat Commun; 2020 Nov; 11(1):5588. PubMed ID: 33149112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. α-Hemolysin-Aided Oligomerization of the Spike Protein RBD Resulted in Improved Immunogenicity and Neutralization Against SARS-CoV-2 Variants.
    Zou J; Jing H; Zhang X; Liu Y; Zhao Z; Duan L; Yuan Y; Chen Z; Gou Q; Xiong Q; Li S; Yang F; Zeng H; Zou Q; Zhang J
    Front Immunol; 2021; 12():757691. PubMed ID: 34630436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19.
    Esparza TJ; Chen Y; Martin NP; Bielefeldt-Ohmann H; Bowen RA; Tolbert WD; Pazgier M; Brody DL
    MAbs; 2022; 14(1):2047144. PubMed ID: 35289719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Screening of potent neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries.
    Pan Y; Du J; Liu J; Wu H; Gui F; Zhang N; Deng X; Song G; Li Y; Lu J; Wu X; Zhan S; Jing Z; Wang J; Yang Y; Liu J; Chen Y; Chen Q; Zhang H; Hu H; Duan K; Wang M; Wang Q; Yang X
    Cell Discov; 2021 Jul; 7(1):57. PubMed ID: 34315862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Computational design and modeling of nanobodies toward SARS-CoV-2 receptor binding domain.
    Yang J; Zhang Z; Yang F; Zhang H; Wu H; Zhu F; Xue W
    Chem Biol Drug Des; 2021 Jul; 98(1):1-18. PubMed ID: 33894099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structures of synthetic nanobody-SARS-CoV-2-RBD complexes reveal distinct sites of interaction and recognition of variants.
    Ahmad J; Jiang J; Boyd LF; Zeher A; Huang R; Xia D; Natarajan K; Margulies DH
    Res Sq; 2021 Jun; ():. PubMed ID: 34159326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Computational design of a neutralizing antibody with picomolar binding affinity for all concerning SARS-CoV-2 variants.
    Jeong BS; Cha JS; Hwang I; Kim U; Adolf-Bryfogle J; Coventry B; Cho HS; Kim KD; Oh BH
    MAbs; 2022; 14(1):2021601. PubMed ID: 35030983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allosteric Determinants of the SARS-CoV-2 Spike Protein Binding with Nanobodies: Examining Mechanisms of Mutational Escape and Sensitivity of the Omicron Variant.
    Verkhivker G
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neutralizing Human Antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 Isolated from a Human Synthetic Fab Phage Display Library.
    Kim YJ; Lee MH; Lee SR; Chung HY; Kim K; Lee TG; Kim DY
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.